ProCE Banner Activity

Identification and Treatment of Advanced NSCLC With EGFR Exon 20 Insertion Mutations

Slideset Download
Download these slides from a live symposium at ONS 2022 featuring best testing practices for advanced NSCLC and the latest evidence on novel therapies available for the treatment of EGFR ex20ins–positive disease.

Released: April 29, 2022

Expiration: April 28, 2023

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Takeda Pharm USA

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Genzyme/Sanofi, iTeos, and Surface and funds for research support to his institution from Amgen, Johnson & Johnson, Merck, Novartis, OncoMed, Roche, and Trizell.